Sam-A Pharm Co Ltd

Sam-A Pharm Co Ltd maintains a strong liquidity position with a current ratio of 9.78, indicating ample short-term assets to cover liabilities. The company's cash and equivalents amount to KRW 6,580,472,210, while its long-term debt is relatively low at KRW 6,942,113,640. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. The company's profitability is reflected in a return on equity (ROE) of 5.67% and a return on assets (ROA) of 5.24%. These figures are in line with the industry's preferred metrics, which emphasize ROIC and ROE as key indicators of capital efficiency. The price-to-book ratio of 0.43 suggests the company is trading at a discount to its book value, which may indicate undervaluation or asset-heavy operations. Sam-A Pharm Co Ltd's revenue is concentrated in its core pharmaceuticals business, with no disclosed segment breakdown. The company's geographic exposure is primarily domestic, as it is based in South Korea and does not report significant international revenue. This concentration may limit growth opportunities but also reduces exposure to foreign exchange and geopolitical risks. The company's growth trajectory is modest, with no specific revenue growth projections provided in the outlook. Historical revenue data shows a stable performance, but the absence of forward-looking guidance makes it difficult to assess future growth potential. The company's capital expenditure is negative, indicating asset disposals or reduced investment in physical infrastructure. The risk assessment highlights a medium liquidity risk due to the negative net cash position after subtracting total debt. The dilution risk is low, as the company has not issued additional shares recently, and there is no indication of dilution pressure in the near term. The debt-to-equity ratio of 0.03 suggests a conservative capital structure with minimal leverage. Recent filings and transcripts do not indicate any material events or strategic shifts. The company's operations remain focused on its core pharmaceuticals business, with no significant new product launches or market expansions disclosed in the latest financial reports.